Discrete element simulation and experimental study of powder spreading process in additive manufacturing

Powders used in additive manufacturing (AM) are spread into a compact layer of particles for sintering and this process is repeated layer by layer to form the final products. Spreading of rod-shaped particles in realistic AM settings is simulated using the discrete element method (DEM) to investigate the effects of particle shape and operating conditions on the bed quality, characterised by its surface roughness and solid volume fraction. It is discovered that larger particle aspect ratios, Ar, or higher spreader translational velocities result in a lower bed quality, i.e. a larger surface roughness and a smaller volume fraction. The surface roughness increases monotonically with Ar. However, the volume fraction exhibits a maximum at Ar = 1.5 for randomly packed powder beds that are formed by the roller type spreaders moving at low translational velocities. It is also found that a roller outperforms a blade spreader in terms of the quality of the prepared bed at the same operating conditions. The micro-structural analysis of the beds also shows particle alignment in response to the induced flow, which is qualitatively confirmed by a set of purposely-designed experiments. In addition, a shape segregation is documented for powders with mixed aspect ratios (Ar) such that particles with larger Ar tend to accumulate on the upper layers of the bed

Auditory Processing Abilities of Medium Security Inmates

This was a pioneer study whose purpose was to investigate the auditory processing abilities of inmates residing in a medium security prison using the SCAN-A: A Test for Auditory Processing Disorders in Adolescents and Adults. Subject selection criteria was met if the subject passed an otoscopic examination and a pure tone threshold hearing screening. Forty-one inmates, with a mean age of 33.1, met the selection criteria. The SCAN-A was administered according to the examiner manual specifications. Responses were recorded for later quantitative analysis. Scores for the auditory figure-ground, competing words, and competing sentences subtests, and the total test were significantly lower than scores for the nonnative sample. Subjects were judged to have questionable to disordered central auditory processing abilities. Findings should be interpreted cautiously because of questions raised regarding the structure of the SCAN-A. Further investigation of the prevalence of central auditory processing disorder (CAPD) within the prison system is warranted

Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1

Background: Immune checkpoint therapy has dramatically changed treatment options in patients with metastatic melanoma. However, a relevant part of patients still does not respond to treatment. Data regarding the prognostic or predictive significance of preexisting immune responses against tumour antigens are conflicting. Retrospective data suggested a higher clinical benefit of ipilimumab in melanoma patients with preexisting NY-ESO-1-specific immunity. Patients and methods: Twenty-five patients with previously untreated or treated metastatic melanoma and preexisting humoural immune response against NY-ESO-1 received ipilimumab at a dose of 10 mg/kg in week 1, 4, 7, 10 followed by 3-month maintenance treatment for a maximum of 48 weeks. Primary endpoint was the disease control rate (irCR, irPR or irSD) according to immune-related response criteria (irRC). Secondary endpoints included the disease control rate according to RECIST criteria, progression-free survival and overall survival (OS). Humoural and cellular immune responses against NY-ESO-1 were analysed from blood samples. Results: Disease control rate according to irRC was 52%, irPR was observed in 36% of patients. Progression-free survival according to irRC was 7.8 months, according to RECIST criteria it was 2.9 months. Median OS was 22.7 months; the corresponding 1-year survival rate was 66.8%. Treatment-related grade 3 AEs occurred in 36% with no grade 4-5 AEs. No clear association was found between the presence of NY-ESO-1-specific cellular or humoural immune responses and clinical activity. Conclusion: Ipilimumab demonstrated clinically relevant activity within this biomarker-defined population. NY-ESO-1 positivity, as a surrogate for a preexisting immune response against tumour antigens, might help identifying patients with a superior outcome from immune checkpoint blockade. (C) 2017 Elsevier Ltd. All rights reserved